Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:IMGN

ImmunoGen (IMGN) Stock Price, News & Analysis

ImmunoGen logo

About ImmunoGen Stock (NASDAQ:IMGN)

Advanced Chart

Key Stats

Today's Range
$31.23
$31.23
50-Day Range
$31.23
$31.23
52-Week Range
$3.61
$31.25
Volume
40 shs
Average Volume
8.78 million shs
Market Capitalization
$8.32 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.

Receive IMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter.

IMGN Stock News Headlines

Only a handful of people know the setup that's defied these chaotic markets.
Since February, we've hit 28 out of 29 trades – that's a 96% win rate taking simple options setups on one single ticker every day. That's why Jack Carter and I teamed up to reveal The 4PM Payout Plan. Our goal here was to show you how to take these daily setups every morning to collect a 4PM payout. Naturally, no one can guarantee what the market does in the future… But these simple daily options setups have paid out with the market rallying, dropping, or staying flat. And if you want to be one of the few to not just know the ropes behind these daily setups but also deploy them for yourself…
Artisan International Small-Mid Instl
Artisan International Small-Mid Advisor
See More Headlines

IMGN Stock Analysis - Frequently Asked Questions

ImmunoGen, Inc. (NASDAQ:IMGN) posted its earnings results on Monday, July, 31st. The biotechnology company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.16) by $0.14. The business's revenue for the quarter was up 485.9% compared to the same quarter last year.
Read the conference call transcript
.

ImmunoGen subsidiaries include Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp..

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmunoGen investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), GE Aerospace (GE), Arista Networks (ANET) and Adobe (ADBE).

Company Calendar

Last Earnings
7/31/2023
Today
5/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:IMGN
Employees
277
Year Founded
1981

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
390.38
P/E Growth
N/A
Net Income
-$222.93 million
Pretax Margin
-25.24%

Debt

Sales & Book Value

Annual Sales
$287.61 million
Price / Cash Flow
N/A
Book Value
$0.71 per share
Price / Book
43.99

Miscellaneous

Free Float
252,764,000
Market Cap
$8.32 billion
Optionable
Optionable
Beta
1.18

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:IMGN) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners